NDATopicalLotion
Approved
Oct 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8
Data completeness
3/8 — Basic
LOTRIMIN AF (clotrimazole) by Merck & Co. is clinical pharmacology clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and malassezia furfur . First approved in 1989.
Drug data last refreshed 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOTRIMIN AF is a topical antifungal lotion containing clotrimazole, a broad-spectrum azole that disrupts fungal cell membrane synthesis. It is indicated for dermatophyte and candida infections including athlete's foot, jock itch, ringworm, and candidiasis. The drug works by inhibiting fungal cytochrome P450-mediated ergosterol synthesis, causing rapid leakage of intracellular contents and cell death.
LOE Approaching
Product approaching loss of exclusivity with declining commercial momentum; supporting teams may face consolidation or reallocation to newer antifungal platforms.
Mechanism of Action
CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of pathogenic dermatophytes, yeasts, and Malassezia furfur . The primary action of clotrimzole is against dividing and growing organisms. In vitro ,…
Worked on LOTRIMIN AF at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.